ImmunityBio

ImmunityBio is a San Diego, California-based immunotherapy company focused on the development of therapies to treat cancers and infectious diseases. The company develops cell and immunotherapy products with the aim of strengthening the body's immune system and believes that the activation of the innate immune system is key to developing immunological memory.

ImmunityBio's mission is "to continuously pursue new therapies that kill disease, not the immune system." Many therapies, such as radiation and chemotherapy, are known to harm the immune system; ImmunityBio aims to develop treatments that can target diseases, while at the same time building the body's natural defenses. Many of the therapies developed by ImmunityBio can be administered in an outpatient setting, rather than a hospital.

The company is led by Rich Adcock, who serves as president and chief executive officer. The company is part of the NantWorks group of companies and is active in both the United States and Europe. ImmunityBio’s immunotherapies are currently being studied in a range of clinical trials at various stages.

ImmunityBio was founded in 2014 by Dr. Patrick Soon-Shiong. In addition to serving as the company's executive chairman, and global chief scientific and medical officer, Dr Soon-Shiong is

known for inventing the protein nanoparticle drug, Abraxane. In March 2021, ImmunityBio and NantKwest, Inc. (both owned by Dr. Soon-Shiong) completed a merger and began operating under the name ImmunityBio. The company's shares of common stock commenced trading on NASDAQ on March 10, 2021, under the new ticker “IBRX.”